medRxiv preprint doi: https://doi.org/10.1101/2020.07.07.20148221; this version posted May 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. 1 Growth Differentiation Factor-15 as a candidate biomarker in gynecologic 1 malignancies: A meta-analysis 2 Dipayan Roy MD,¹ Anupama Modi M.Sc.,¹ Manoj Khokhar M.Sc.,¹ Manu Goyal MD DNB,² 3 Shailja Sharma MD,¹ Purvi Purohit PhD,^{*1} Puneet Setia MD,³ Antonio Facciorusso MD PhD,⁴ 4 Praveen Sharma PhD¹ 5 6 Author affiliations: 7 ¹Department of Biochemistry, AIIMS Jodhpur, India ²Department of Obstetrics & Gynaecology, AIIMS Jodhpur, India 8 9 ³Department of Forensic Medicine & Toxicology, AIIMS Jodhpur, India 10 ⁴Gastroenterology Unit, University of Foggia, Italy 11 **ORCiD**: 12 13 Dipayan Roy: https://orcid.org/0000-0002-3429-1470 14 Anupama Modi: https://orcid.org/0000-0002-6488-4701 15 Manoj Khokhar: https://orcid.org/0000-0001-7106-8545 16 Manu Goyal: https://orcid.org/0000-0002-8691-1790 17 Purvi Purohit: https://orcid.org/0000-0001-8559-2911 18 Puneet Setia: https://orcid.org/0000-0002-0849-0759 19 Antonio Facciorusso: https://orcid.org/0000-0002-2107-2156 20 Praveen Sharma: https://orcid.org/0000-0002-8324-737X 21 22 *Corresponding author & contact details: 23 Dr. Purvi Purohit 24 Additional Professor 25 The Department of Biochemistry 26 AIIMS, Jodhpur

- 27 E-mail: dr.purvipurohit@gmail.com
- 28
- 29 Word count: manuscript- 4,760 (whole), 2,354 (without title page, abstract, references, tables,
- 30 figures and figure legends), abstract- 99, references- 49, tables- 3, figures- 3

31

32 **Funding information**: This study was not funded.

33

34 Abstract:

35 Growth Differentiation Factor-15 (GDF-15), though emerged as a novel marker in gynecological 36 cancers, is yet to be recognized in clinical diagnostics. Eligible studies were sorted from multiple 37 online databases, namely PubMed, Cochrane, ClinicalTrials.gov, Google Scholar, Web of Science, 38 Embase, Scopus, LILACS, OpenGrey. From six studies, histopathologically diagnosed cases 39 without prior treatment, and with diagnostic accuracy data for GDF-15 in gynecological cancers, 40 were included. Our meta-analysis shows that GDF-15 has pooled diagnostic odds ratio of 12.74 at 41 80.5% sensitivity and 74.1% specificity, and an AUC of 0.84. Hence, GDF-15 is a potential marker 42 to differentiate gynecological malignancy from non-malignant tumors. 43

- 44 Keywords: Biostatistics, Cancer Biomarkers, Detection/Diagnosis, Ovarian Cancer, GDF-15, MIC-
- 45 1, NAG-1, PLAB, PTGFB

3

46 **1. Introduction**

47 Cancers of the ovary, fallopian tube, body of uterus, cervix, vagina, and vulva come under the broad 48 heading of cancers of the female reproductive system. They are one of the major causes of cancer-49 related mortality, accounting for 13.1% of age-standardized cancer-related deaths in females (1). 50 The difficulty of detecting cancer in its early stages is the primary factor for poor clinical outcomes 51 (2). Biomarkers contribute to the management of these cancers by pre-operative differentiation 52 between benign and malignant pelvic masses, progression of malignancy, monitoring response to 53 treatment and recurrence, and most importantly, attempting to detect disease at an earlier stage (3). 54 To date, there are no such biomarkers widely used in clinical settings of gynecological 55 malignancies.

56 Serum cancer antigen 125 (CA125) has been in use as a biomarker for clinical diagnosis and 57 monitoring of treatment response in epithelial ovarian carcinoma (EOC), but its sensitivity as an 58 independent marker is suboptimal in early-stage post-menopausal women (3-5). Endometrial cancer 59 incidence is on the rise worldwide. Early diagnosis can significantly improve its outcome as 5-year 60 survival is >90% in early-stage disease. Existing markers (e.g., leptin, adiponectin, and prolactin) 61 for detection or monitoring are subject to hormonal and metabolic alterations and not unique to 62 cancer development (6). Also, cervical cancer is one of the leading causes of female cancer-related 63 mortality. Although the conventional tumor marker, squamous cell carcinoma is a useful prognostic 64 marker, its role in early diagnosis is limited (7).

Human Growth Differentiation Factor-15 (GDF-15), also known as Macrophage Inhibitory Cytokine (MIC-1), non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1), placental bone morphogenetic protein (PLAB), placental transforming growth factor-beta (PTGFB), prostate derived factor (PDF), and PL-74 is a member of the Transforming Growth Factor- β (TGF- β) superfamily (8, 9). Under normal conditions, GDF-15 is only found in large amounts in the placenta (10). It is also a stress-responsive cytokine that is not only highly expressed in inflammatory conditions but has emerged as a potential marker in cancer diagnosis and progression

4

72 (9, 11, 12). Recently, several studies have demonstrated it to be involved in different gynecological 73 malignancies such as EOC (4, 13-16), endometrial carcinoma (17), uterine sarcoma (18), and 74 cervical cancer (19), where it is seen to be increased in serum or upregulated in tissue in case of 75 malignant tumors compared to non-malignant ones. Hence, its applicability as a biomarker that can 76 differentiate a benign mass from a malignant one and aid in the early detection of gynecological 77 malignancies would be a significant advancement. Recently, Maeno et al. (20) developed a novel, 78 flow-through membrane immunoassay-based measurement system for GDF-15 for the screening of 79 uterine sarcoma. This chemiluminescence assay-based method correlated well with the GDF-15 80 measurements from ELISA (18). Nevertheless, the inconsistency of the data across different studies 81 prevents us from pinpointing its clinical relevance in these patients. We have compiled original 82 articles citing the role of GDF-15 in cancers of the female reproductive tract and performed a 83 systematic analysis to evaluate its importance as a diagnostic biomarker.

84 2. Materials and Methods

85 2.1 Data sources and eligibility criteria

86 We conducted this study following the Meta-analysis Of Observational Studies in Epidemiology 87 (MOOSE) and Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic 88 Test Accuracy Studies (PRISMA-DTA) guidelines (21, 22). Two independent reviewers performed 89 a selective literature search on several databases (Pubmed, Cochrane, ClinicalTrials.gov, Google Scholar, Web of Science, Embase, Scopus, LILACS, Opengrey) during 16th-20th March 2019. All 90 91 relevant articles were screened as per titles and abstracts and subsequently reviewed for eligibility after they were combined and imported to Rayyan QCRI software (23). MeSH terms or keywords 92 93 used in the search were (("Growth Differentiation Factor-15" OR "GDF-15" OR "Macrophage 94 Inhibitory Cytokine-1" OR "MIC-1" OR "NSAID-activated gene-1" OR "NAG-1" OR "placental 95 transforming growth factor-beta" OR "PTGFB" OR "placental bone morphogenetic protein" OR "PLAB" OR "prostate derived factor" OR "PDF" OR "PL-74") AND ("Ovarian cancer" OR 96 97 "Ovarian carcinoma" OR "Endometrial cancer" OR "Endometrial carcinoma" OR "Uterine cancer"

5

98 OR "Uterine Carcinoma" OR "Cervical cancer" OR "Cervical carcinoma") AND ("diagnosis" OR 99 "sensitivity" OR "specificity" OR "prognosis" OR "outcome")). References of identified articles 100 and related reviews were manually searched for articles that may have been left out. The entire search strategy was carried out again latest on 3rd April 2021 for new articles which may have been 101 102 left out of the analyses. No such study was found. 103 2.2 Study selection 104 The selection procedure is schematically depicted according to the PRISMA 2020 flow diagram 105 (Figure 1) (24). Full-text studies were included as long as they met the following criteria: (1) 106 included cases that were first identified without prior treatment; (2) proven diagnosis by pathology; 107 (3) studies reported diagnostic feature of GDF-15 in cancers of the female reproductive tract; (4)

108 sufficient data for describing or calculating Sensitivity, Specificity, and Area Under Curve (AUC);

109 (5) studies approved by an Ethics Committee or Institutional Review Board, i.e. studies must have

110 mentioned that written informed consent had been taken from all subjects before inclusion.

111 Accordingly, exclusion criteria were- (1) studies in which patient received therapy, (2) studies with

112 insufficient data, and also, failure to contact the authors, (3) studies with <10 cases, (4) duplicate

- 113 publications, (5) non-clinical research, animal studies, reviews, conference abstracts, case reports,
- 114 meta-analyses.

115 Registration detail: PROSPERO, CRD42019130097.

116 2.3 Data collection

Data were extracted from articles in the form of the lead author, year of publication, country of the study population, the number of patients, sample type, method of testing, sensitivity, specificity, cut-off value, and AUC by two independent reviewers. In the articles where sensitivity and specificity were not explicitly mentioned, they were extracted from the AUC curve using the Engauge Digitizer software (25) or manually calculated from other measures of diagnostic accuracy available in the articles (26) or both. Efforts were made to contact the authors of the original articles for the missing data but to no avail. In cases where a study had data for multiple comparisons, only

6

124 one comparison was chosen in the final analysis considering the relevance to our research topic,

125 heterogeneity issues and to avoid a unit-of-analysis error (27). All disagreements were resolved by

126 discussion or consensus with a third reviewer.

127 2.4 Assessment of risk of bias

Quality assessment and risk of bias of the studies were evaluated by the revised Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) criteria (28) according to the designated points viz. patient selection, index test, reference standard, and flow and timing. All relevant evidence were included in the final analysis (28).

132 2.5 Data analysis

133 Previously published guidelines and methods for conducting a meta-analysis of diagnostic test 134 accuracy were consulted (29-31). Analyses were performed on Review Manager 5.3 (RevMan 5.3) 135 (32), R programming platform with the aid of R packages meta and mada (Meta-Analysis of 136 Diagnostic Accuracy) (33-37) and the MetaDTA online tool as described by Freeman et al. (38). 137 The primary outcomes were obtained as pooled sensitivity, specificity, positive likelihood ratio 138 (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and AUC with corresponding 139 95% confidence intervals (CI) by grouping the data from the studies. The bivariate model (39) for 140 calculating summary measures in diagnostic accuracy studies was used for the analysis. Statistically significant heterogeneity among the studies was verified using Cochran's Q and I^2 statistics and a 141 142 fixed or random-effects model was chosen accordingly. Funnel plot asymmetry for the examination 143 of publication bias was not performed as the number of included studies was less than 10 (40). 144 For all analytical purposes, p < 0.05 was considered statistically significant.

145 **3. Results**

146 3.1 Study selection

One hundred ninety-six (196), potentially relevant studies were retrieved in our search (Figure 1).
They were scanned for titles, keywords, abstracts, and a total of one hundred eighty-four (184)
studies were eliminated because they were either duplicates, out of scope or basic or animal model

7

150 studies. The remaining 12 studies were read in detail, and finally, 6 of them, comprising 923 cases

151 of gynecological cancers and 465 non-cancer controls, were considered eligible for diagnostic meta-

analysis according to our inclusion criteria.

153 3.2 Study characteristics

154 The study characteristics are summarized in Table 1. In the six diagnostic studies finally included, 155 the study participants involved Chinese (4, 15), Polish (13), Norwegian (14, 17, 18), and Belgian 156 (18) patients, suffering from ovarian carcinoma (4, 13-15), endometrial carcinoma (17), and uterine 157 sarcoma (18). The final diagnosis was all confirmed histologically and staged according to the 158 International Federation of Gynecology and Obstetrics (FIGO) staging. The control group was non-159 cancer controls and comprised of healthy pre-and post-menopausal controls, benign ovarian tumors, 160 and benign leiomyoma. Samples were either EDTA plasma (14, 17, 18), serum (4, 15), or peritoneal 161 fluid (13). Enzyme-linked Immunosorbent Assay (ELISA) was primarily used to measure GDF-15,

while one group each used immunoradiometric assay (IRMA) and multiplex immunoassay (13, 14).

163 The diagnostic measures were sensitivity, specificity, and AUC. Only three out of the six studies

164 provided a cut-off value of GDF-15, ranging from 519.6 pg/mL to 748 pg/mL (4, 14, 15).

165 **3.3 Risk of bias of included studies**

166 The studies were assessed for quality using the QUADAS-2 list (Table 3). According to the 167 QUADAS-2 assessment, five out of six studies were at risk of bias, whereas only one study showed 168 concern regarding applicability. All studies were included for further statistical analysis.

169 3.4 Synthesis of results

170 The Higgins' I^2 for the diagnostic odds ratio of all studies was 86.5% (95% CI 72.8%-93.3%,

171 p < 0.01), indicating considerable heterogeneity in the pooled data. Values ranging from 60.9% to

172 90.6% were also detected in other subgroups in the diagnostic data. Hence, we resorted to using the

173 random-effects model for the studies.

174 The measures of diagnostic accuracy for the included studies are depicted in Table 2 and Figure 2.

175 The overall pooled sensitivity, specificity, diagnostic odds ratio (DOR) and area under the curve

8

(AUC) for GDF-15 used to distinguish gynecological cancers from non-cancerous tumors, were 0.805 (95% CI: 0.711-0.873), 0.741 (95% CI: 0.611-9.839), 12.738 (95% CI: 5.034-32.231), and 0.835 respectively, corresponding to a positive likelihood ratio (PLR) of 3.103 (95% CI: 1.671-4.535) and a negative likelihood ratio (NLR) of 0.264 (95% CI: 0.146-0.383). The summary ROC curve is shown in Figure 3. These results suggest that GDF-15 levels can be used as a useful alternative biomarker in diagnosing cancers of the female reproductive tract compared to noncancerous tumors.

183 **4. Discussion**

Our study has identified six original articles which evaluated the role of GDF-15 as a candidate biomarker in diagnosing malignancies of the female reproductive tract from non-malignant tumors. We performed a meta-analysis and found it to be a potential robust biomarker with a pooled sensitivity and specificity of 80.5% and 74.1%, respectively. One study (14) had a 'low risk' of bias and applicability across all domains in the QUADAS-2 assessment. Five other studies had either 'unclear' or 'high' risk of bias in one of the four domains, among which Staff et al. (17) also had one 'unclear' applicability concern. We also found significant heterogeneity across the studies.

191 Malignancies of the female reproductive tract are one of the major causes of cancer-related 192 mortality in females, mainly because these cancers are diagnosed at later stages (1, 2). Pre-operative 193 detection of malignant lesions is also crucial for optimal management. Furthermore, the disease-free 194 survival (DFS) of EOC patients is often poor even after extensive resection (41). Several systematic 195 reviews in the past have elaborated the role of existing biomarkers or combinations thereof in 196 ovarian or endometrial cancers alone (42-45). CA125 as a diagnostic biomarker to differentiate 197 malignant and borderline ovarian tumors from benign lesions showed a promising sensitivity and 198 specificity of 80% and 75%, respectively (45), which is comparable to our pooled estimates. 199 Nevertheless, to our knowledge, a marker potent enough to discriminate malignant gynecological 200 tumors in early stages from non-malignant ones without compromising on either sensitivity or 201 specificity is not yet described. Several groups have proposed GDF-15 as a biomarker in prostatic,

9

202 colorectal, hepatocellular, and pancreatic carcinomas as well as other malignancies and non-203 malignant inflammatory conditions (46, 47). Therefore, it is clear from the existing evidence that 204 GDF-15 may not be specific for any single cancer type. However, GDF-15 is substantially 205 increased or upregulated across all gynecological malignancies. Thus, it can be used as a 206 complementary diagnostic biomarker in addition to existing diagnosing strategies, wherein it may 207 be a useful biomarker in the diagnosis of early-stage EOC from benign ovarian tumors and other 208 non-cancerous tumors of the female reproductive tract in such scenarios. In our study, the pooled 209 sensitivity was comparably close with the sensitivity values of GDF-15 across all articles which 210 were taken for analysis. While two articles on ovarian carcinoma showed the specificity of GDF-15 211 to be below 60% (13, 14), the pooled specificity came out to be 74.1%, possibly because of sizeable 212 inter-study variation.

213 There are certain limitations to our study. There were low sample sizes for individual cancer types. 214 Most of the studies were at risk of bias, primarily due to a case-control design, which is known to 215 exaggerate diagnostic accuracy (48, 49). So far, the studies have been confined only to Chinese and 216 European populations. Thus, a small sample with such a highly selective population will require 217 further validation studies to establish its applicability in diagnosis in a clinical setting. Studies on a 218 large scale need to be carried out in other populations. In our review, we could not include studies 219 on all the cancers of the female reproductive system, namely cervical and vulval cancers, as data 220 were either not present or did not fit our inclusion criteria. Furthermore, studies on in-vitro models 221 and animal models were also left out. Patients with treatment history had to be excluded as anti-222 cancer therapy may alter the expression levels of GDF-15.

The applicability of GDF-15 can be verified with future prospective studies focusing on larger sample size and patient ethnicities. Finally, before implementing it into clinical practice, cut-off values for GDF-15 must be determined and internationally validated. Here, the cut-off value to differentiate between malignant and non-malignant tumors or healthy controls is mentioned in only three of the six studies included. Large scale prospective cohorts, then, are necessary to validate a

- 228 uniform cut-off. To summarize, our analysis suggests that GDF-15 may be a useful candidate
- 229 marker to differentiate malignant from non-malignant tumors of the female reproductive system.

- 230 Acknowledgement: None.
- 231 **Disclosure of interest**: The authors report no conflict of interest.

12

232 **References:**

- 233 1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global
- 234 Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
- 235 Cancers in 185 Countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi:10.3322/caac.21492
- 236 2. Mishra K. Gynaecological malignancies from palliative care perspective. *Indian J Palliat Care*.
- 237 2011;17(Suppl):S45–S51. doi:10.4103/0973-1075.76243
- Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian
 cancer. *Expert Rev Mol Diagn*. 2017;17(6):577–591. doi:10.1080/14737159.2017.1326820
- 240 4. Zhao, D., Wang, X. & Zhang, W. GDF15 predict platinum response during first-line
- chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in
- 242 epithelial ovarian cancer. *BMC Cancer* 18, 328 (2018) doi:10.1186/s12885-018-4246-4
- 5. E. Hogdall. Cancer antigen 125 and prognosis, *Curr. Opin. Obstet. Gynecol.* 20 (1) (2008) 4–8.
- 244 6. Townsend MH, Ence ZE, Felsted AM, Parker AC, Piccolo SR, Robison RA, O'Neill KL.
- 245 Potential new biomarkers for endometrial cancer. *Cancer Cell Int.* 2019;19:19. Published 2019
- 246 Jan 21. doi:10.1186/s12935-019-0731-3
- Iida, M., Banno, K., Yanokura, M., Nakamura, K., Adachi, M., Nogami, Y., Umene, K.,
 Masuda, K., Kisu, I., Iwata, T., et al. (2014). Candidate biomarkers for cervical cancer
 treatment: Potential for clinical practice (Review). *Mol Clin Oncol.* 2, 647-655.
 doi:10.3892/mco.2014.324
- 8. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory
 cytokine, is a divergent member of the TGF-beta superfamily. *Proc Natl Acad Sci U S A*.
 1997;94:11514–9.
- Adela R, Banerjee SK. GDF-15 as a target and biomarker for diabetes and cardiovascular
 diseases: a translational prospective. *J Diabetes Res.* 2015; 2015:490842.
- 256 10. Lawton LN, Bonaldo MF, Jelenc PC, Qiu L, Baumes SA, Marcelino RA, de Jesus GM,
- 257 Wellington S, Knowles JA, Warburton D, et al. Identification of a novel member of the TGF-

- beta superfamily highly expressed in human placenta. *Gene* 1997;1:17–26. doi: 10.1016/s0378-
- 259 1119(97)00485-x
- 260 11. Modi, A., Dwivedi, S., Roy, D., Khokhar, M., Purohit, P., Vishnoi, J., Pareek, P., Sharma, S.,
- 261 Sharma, P., Misra, S. (2019). Growth differentiation factor 15 and its role in carcinogenesis: an
- 262 update. *Growth Factors*, 2019 Aug;37(3-4):190-207. doi:10.1080/08977194.2019.1685988
- 263 12. Modi A, Roy D, Purohit P, Pareek P, Vishnoi J. Analysis of Serum Growth Differentiation
- 264 Factor-15 in Progression of Breast Cancer in Type II Diabetes Mellitus Patients. *Metabolism*.
- 265 March 2021; 116(Suppl):154538. <u>doi</u>:10.1016/j.metabol.2020.154538.
- 266 13. Chudecka-Głaz AM, Cymbaluk-Płoska AA, Menkiszak JL, Pius-Sadowska E, Machaliński BB,
- 267 Sompolska-Rzechuła A, Rzepka-Górska IA. Assessment of selected cytokines, proteins, and
- growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological
- 269 conditions. *Onco Targets Ther*. 2015 Feb 23;8:471-485. doi: 10.2147/OTT.S73438.
- 270 14. Staff, A. C., Bock, A. J., Becker, C., Kempf, T., Wollert, K. C., & Davidson, B. (2010). Growth
- differentiation factor-15 as a prognostic biomarker in ovarian cancer. *Gynecol Oncol*, 118(3),
- 272 237–243. doi:10.1016/j.ygyno.2010.05.032
- 273 15. Zhang Y, Hua W, Niu LC, Li SM, Wang YM, Shang L, Zhang C, Li WN, Wang R, Chen BL,
- et al. Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial
 ovarian cancer patients. *Tumour Biol.* 2016 Jul;37(7):9423-9431. doi: 10.1007/s13277-0154699-x.
- 16. Lima CA, Jammal MP, Martins-Filho A, Silveira TP, Micheli DC, Tavares-Murta BM, Murta
- 278 EFC, Nomelini RS. Stromal Growth Differentiation Factor 15 and Its Association with Ovarian
- 279 Cancer. *Gynecol Obstet Invest*. 2018;83(1):35-39. doi: 10.1159/000473891.
- 17. Staff AC, Trovik J, Eriksson AG, Wik E, Wollert KC, Kempf T, Salvesen HB. Elevated plasma
 growth differentiation factor-15 correlates with lymph node metastases and poor survival in
 endometrial cancer. *Clin Cancer Res.* 2011 Jul 15;17(14):4825-4833. doi:10.1158/10780432.CCR-11-0715.

- 284 18. Trovik, J., Salvesen, H. B., Cuppens, T., Amant, F., & Staff, A. C. (2014). Growth
- 285 Differentiation Factor-15 as Biomarker in Uterine Sarcomas. Int J of Gynecol Cancer, 24(2),
- 286 252–259. doi:10.1097/igc.000000000000037
- 287 19. Li S, Ma YM, Zheng PS, Zhang P. (2018). GDF15 promotes the proliferation of cervical cancer
- cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2. *J Exp Clin Cancer Res*,
- 289 37(1):80. doi:10.1186/s13046-018-0744-0
- 290 20. Maeno M, Mizutani T, Tsuyoshi H, Yamada S, Ishikane S, Kawabe S, Nishimura K, Yamada
- 291 M, Miyamoto K, Yoshida Y. Development of a novel and rapid measurement system for
- growth differentiation factor-15, progranulin, and osteopontin in uterine sarcoma. *Endocr J*.
- 293 2020 Jan 28;67(1):91-94. doi: 10.1507/endocrj.EJ18-0572.
- 294 21. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D. Meta-analysis of
- observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational
 Studies in Epidemiology (MOOSE) group. *JAMA* 2000;283: 2008–2012.
- 297 22. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, The PRISMA-DTA Group
- 298 (2018). Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic
- Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018 Jan 23;319(4):388-396.
- doi: 10.1001/jama.2017.19163.
- 301 23. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for
 302 systematic reviews. *Syst Rev.* 2016 Dec 5;5(1):210. doi: 10.1186/s13643-016-0384-4.
- 303 24. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L,
- Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for
 reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71
- 306 25. Mark Mitchell, Baurzhan Muftakhidinov and Tobias Winchen et al, "Engauge Digitizer
 307 Software." Webpage: http://markummitchell.github.io/engauge-digitizer, Last Accessed: April
 308 3, 2021

- 309 26. Šimundić A. M. (2009). Measures of Diagnostic Accuracy: Basic Definitions. *EJIFCC*, 19(4),
- 310 203–211.
- 311 27. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).
- 312 *Cochrane Handbook for Systematic Reviews of Interventions* version 6.0 (updated July 2019).
- 313 Cochrane, 2019. Available from www.training.cochrane.org/handbook.
- 28. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM,
- 315 Sterne JA, Bossuyt PM; QUADAS-2 Group. QUADAS-2: a revised tool for the quality
- assessment of diagnostic accuracy studies. Ann Intern Med. 2011 Oct 18;155(8):529-536. doi:
- 317 10.7326/0003-4819-155-8-201110180-00009.
- 318 29. Campbell JM, Klugar M, Ding S, Carmody DP, Hakonsen SJ, Jadotte YT, White S, Munn Z.
- 319 Diagnostic test accuracy: methods for systematic review and meta-analysis. Int J Evid Based
- 320 *Healthc*. 2015 Sep;13(3):154-62. doi: 10.1097/XEB.0000000000000061.
- 321 30. Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, Bezemer PD.
- 322 Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res
- 323 *Methodol* 2002;2:9. doi:10.1186/1471-2288-2-9.
- 31. Chappell FM, Raab GM, Wardlaw JM. When are summary ROC curves appropriate for
 diagnostic meta-analyses? *Stat Med* 2009; 28:2653–2668.
- 326 32. Review Manager Web (RevMan Web). The Cochrane Collaboration, 2019. Available at
 327 revman.cochrane.org
- 328 33. R Core Team (2013). R: A language and environment for statistical computing. R Foundation
 329 for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
- 330 34. RStudio Team (2015). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA
 331 URL *http://www.rstudio.com/*.
- 332 35. Shim SR, Kim SJ, Lee J. Diagnostic test accuracy: application and practice using R software.
- 333 *Epidemiol Health*. 2019;41:e2019007. doi:10.4178/epih.e2019007

- 334 36. Philipp Doebler (2019). mada: Meta-Analysis of Diagnostic Accuracy. R package version 0.5.9.
- 335 https://CRAN.R-project.org/package=mada
- 336 37. Guido Schwarzer (2007), meta: An R package for meta-analysis, R News, 7(3), 40-45.
- 337 38. Freeman SC, Kerby CR, Patel A, Cooper NJ, Quinn T, & Sutton AJ. (2019). Development of
- an interactive web-based tool to conduct and interrogate meta-analysis of diagnostic test
- 339 accuracy studies: MetaDTA. BMC Med Res Methodol, 19(1):81. doi:10.1186/s12874-019-
- 340 0724-x
- 341 39. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, & Zwinderman AH.
- 342 (2005). Bivariate analysis of sensitivity and specificity produces informative summary
- 343 measures in diagnostic reviews. J Clin Epidemiol, 58(10), 982-
- 344 990. doi:10.1016/j.jclinepi.2005.02.022
- 40. Mavridis D, Salanti G. How to assess publication bias: funnel plot, trim-and-fill method and
 selection models. *Evid Based Ment Health*. 2014 Feb;17(1):30. doi: 10.1136/eb-2013-101699.
 PMID: 24477535
- 348 41. Becker DA, Thomas ED, Gilbert AL, Boone JD, Straughn JM Jr, Huh WK, Bevis KS, Leath
- 349 CA 3rd, Alvarez RD. Improved outcomes with dose-dense paclitaxel-based neoadjuvant 350 chemotherapy in advanced epithelial ovarian carcinoma. *Gynecol Oncol.* 2016;142(1):25–29.
- 42. Lan Z, Fu D, Yu X, & Xi M. (2015). Diagnostic values of osteopontin combined with CA125
- for ovarian cancer: a meta-analysis. *Familial Cancer*, 15(2), 221–230. doi:10.1007/s10689-0159847-3
- 43. Hu, L., Du, S., Guo, W., Chen, D., & Li, Y. (2016). Comparison of Serum Human Epididymis
- Protein 4 and Carbohydrate Antigen 125 as Markers in Endometrial Cancer. *Int J Gynecol Cancer*, 26(2), 331–340. doi:10.1097/igc.00000000000621
- 44. Wang, J., Gao, J., Yao, H., Wu, Z., Wang, M., & Qi, J. (2014). Diagnostic accuracy of serum
- 358 HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. *Tumor Biol*, 35(6),
- 359 6127–6138. doi:10.1007/s13277-014-1811-6

- 360 45. Medeiros, L. R., Rosa, D. D., da Rosa, M. I., & Bozzetti, M. C. (2009). Accuracy of CA 125 in
- 361 the diagnosis of ovarian tumors: A quantitative systematic review. *Euro J Obstet Gynecol*
- 362 *Reprod Biol*, 142(2), 99–105. doi:10.1016/j.ejogrb.2008.08.011
- 363 46. Wang Y, Jiang T, Jiang M, Gu S. Appraising growth differentiation factor 15 as a promising
- biomarker in digestive system tumors: a meta-analysis. *BMC Cancer*. 2019 Feb 26;19(1):177.
- 365 doi: 10.1186/s12885-019-5385-y.
- 366 47. Roy D, Purohit P, Modi A, Khokhar M, Shukla RKG, Chaudhary R, Sankanagoudar S, Sharma
- 367 P. Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes
- 368 Mellitus in Indian Subjects: A Case-control Study. *Curr Diabetes Rev.* 2021 Jan 3. doi:
- 369 10.2174/1573399817666210104101739. Epub ahead of print. PMID: 33397240.
- 48. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM.
- 371 Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999 Sep
- 372 15;282(11):1061-6. doi: 10.1001/jama.282.11.1061. Erratum in: JAMA 2000 Apr
- 373 19;283(15):1963. PMID: 10493205.
- 49. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and
- bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med. 2004 Feb
- 376 3;140(3):189-202. doi: 10.7326/0003-4819-140-3-200402030-00010. PMID: 14757617.

18

277	Table 1. Study	1 charactoristics	of all the arti	alaa includad ii	n tha diagnostic mat	a analysia
511	Table 1. Sludy	(characteristics	of all the alth	cies included in	n me magnostic met	a-a11a1y515

Study	Country and recruitm ent period	Design	Group1 (N1)	Group2 (N2)	Method	Cut- off (pg/ mL)	TP	FN	FP	TN	Stagin g	Index test	Refere nce test
Staff 2010 (14)	Norway ; 2003- 2009	Prospe ctive	Ovarian carcino ma (125)	Borderl ine and benign ovarian tumors (187)	EDTA Plasma; IRMA	736	100	25	79	108	25/11/ 71/18	GDF- 15	FIGO
Zhao 2018 (4)	China; 2009- 2013	Retros pectiv e	Epitheli al ovarian carcino ma (122)	Healthy control (120)	Serum; ELISA	519. 6	104	18	14	106	I & II = 13; III & IV = 109	GDF- 15	FIGO
Zhang 2016 (15)	China; 2010- 2013	Retros pectiv e	Epitheli al ovarian carcino ma (120)	Healthy control (40)	Serum; ELISA	748	91	29	7	33	I & II = 41; III & IV = 104	GDF- 15	FIGO
Trovik 2014 (18)	Multice nter (Norwa y, Belgium); 2001- 2010	Prospe ctive case control	Uterine sarcoma (19)	Benign leiomy oma (50)	EDTA Plasma; ELISA	-	16	3	6	34	9/3/3/ 4	GDF- 15	FIGO
Staff 2011 (17)	Norway ; 2003- 2009	Nested case control	Endome trial carcino ma (510)	Healthy control (40)	EDTA Plasma; ELISA	-	319	182	18	32	366/5 7/63/2 4	GDF- 15	FIGO
Chude cka- Glaz 2015 (13)	Poland; NR	Retros pectiv e	Ovarian carcino ma (36)	Benign tumors (38)	Peritone al fluid; Multipl ex	-	34	2	17	21	I & II = 10; III & IV = 26	GDF- 15	FIGO

378 Abbreviations: CA125 = Cancer Antigen 125; ELISA = enzyme linked immunosorbent assay;

379 FIGO = International Federation of Gynecology and Obstetrics; GDF-15 = Growth Differentiation

380 Factor-15; IHC = Immunohistochemistry; IRMA = Immunoradiometric assay; NR = not reported

201		C 1'	• .1 1 . 1 . 1•
≺X I	and Z. Measures	of diagnostic ac	curacy in the selected studies
501		or unagnostic ac	curacy in the selected studies

Study	Sensitivity (95% CI)	Specificity (95% CI)	DOR (95% CI)	AUC
Staff 2010 (14)	0.800 (0.719; 0.866)	0.578 (0.503; 0.649)	5.47 (3.23; 9.25)	0.790
Zhao 2018 (4)	0.853 (0.777; 0.910)	0.883 (0.812; 0.935)	43.75 (20.69; 92.52)	0.913
Zhang 2016 (15)	0.758 (0.672; 0.832)	0.825 (0.672; 0.927)	14.79 (5.92; 36.99)	0.894
Trovik 2014 (18)	0.842 (0.604; 0.966)	0.850 (0.702; 0.943)	30.22 (6.69; 136.52)	0.710
Staff 2011 (17)	0.637 (0.593; 0.679)	0.640 (0.492; 0.771)	3.12 (1.70; 5.71)	0.860
Chudecka-Glaz 2015 (13)	0.944 (0.813; 0.993)	0.553 (0.383; 0.714)	21.00 (4.40; 100.22)	0.752
Pooled data	0.805 (0.711; 0.873)	0.741 (0.611; 0.839)	12.74 (5.03; 32.23)	0.835

382

383 *Abbreviations:* 95% CI = 95% Confidence Interval; AUC = Area under the curve; DOR =

384 Diagnostic odds ratio

20

385 **Table 3:** Evaluation of the risk of bias and applicability concerns of the included diagnostic studies

386 using QUADAS-2

		Risk o	of Bias	Appli	Applicability Concerns			
Study	Patient Selection	Index Test	Reference Flow Standard Timing		Patient Selectio n	Index Test	Reference Standard	
Staff 2010 (14)	Low	Low	Low	Low	Low	Low	Low	
Zhao 2018 (4)	High	Low	Low	Low	Low	Low	Low	
Zhang 2016 (15)	High	Unclear	Low	Low	Low	Low	Low	
Trovik 2014 (18)	Unclear	Low	Low	Low	Low	Low	Low	
Staff 2011 (17)	High	Low	Low	Low	Low	Unclear	Low	
Chudecka- Glaz 2015 (13)	Low	Unclear	Low	Low	Low	Low	Low	



387
388 Figure 1: PRISMA 2020 flow diagram depicting the study selection procedure





	Experin	nental	C	ontrol				
Study	Events	Total	Events	Total	c	Odds Ratio	OR	95%-CI
Chudecka-Glaz 2015	34	51	2	23			21.000	[4.400; 100.224]
Staff 2010	100	179	25	133			5.468	[3.233; 9.250]
Staff 2011	319	337	182	214			3.116	[1.701; 5.709]
Trovik 2014	16	22	3	37			30.222	[6.690; 136.523]
Zhang 2016	91	98	29	62			- 14.793	[5.916; 36.988]
Zhao 2018	104	118	18	124			43.746	[20.685; 92.517]
Random effects model		805		593		-	► 12.738	[5.034; 32.231]
Heterogeneity: $I^2 = 86\%$, τ^2	² = 1.0883	3, p < 0	.01		1 1	1	1	
				0	.01 0.1	1 10	100	
					Diagn	ostic Odds Rati	0	

Figure 2: Forest plots of GDF-15 for the (a) sensitivity, (b) specificity, and (c) diagnostic odds ratio

390 of the pooled data from the included studies

Random Effects Meta-Analysis



391 Figure 3: ROC plot displaying extrapolated SROC curve, the summary estimate for sensitivity and



393 Figure legends

- **Figure 1:** PRISMA 2020 flow diagram depicting the study selection procedure
- 395 Figure 2: Forest plots of GDF-15 for the (a) sensitivity, (b) specificity, and (c) diagnostic odds ratio
- 396 of the pooled data from the included studies
- 397 Figure 3: ROC plot displaying extrapolated SROC curve, the summary estimate for sensitivity and
- 398 specificity, and percentage study weights